(MIR) Mirion Technologies - Overview
Stock: Radiation, Detection, Measurement, Monitoring, Medical, Safety
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 57.3% |
| Relative Tail Risk | -10.7% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.93 |
| Alpha | 29.45 |
| Character TTM | |
|---|---|
| Beta | 1.415 |
| Beta Downside | 1.536 |
| Drawdowns 3y | |
|---|---|
| Max DD | 31.90% |
| CAGR/Max DD | 1.54 |
Description: MIR Mirion Technologies January 10, 2026
Mirion Technologies (NYSE:MIR) designs, manufactures, and services radiation detection, measurement, and monitoring solutions across two primary segments: Medical and Nuclear & Safety. The Medical segment supports cancer-care quality and safety through oncology dosimetry, diagnostic imaging safeguards, and radionuclide therapy equipment, while the Nuclear & Safety segment delivers personal detectors, reactor instrumentation, waste-management tools, and laboratory spectroscopy systems to hospitals, government agencies, utilities, and industrial users worldwide.
Key recent metrics: FY 2023 revenue reached roughly **$1.1 billion**, up about **5 % YoY**, with an operating margin near **9 %**; the company reported a **$480 million backlog**, indicating sustained demand for upgrades to aging nuclear facilities and expanding oncology services. Sector drivers include rising global nuclear-energy capacity (the International Atomic Energy Agency projects a 2 % annual increase through 2030) and heightened regulatory focus on radiation safety in both healthcare and power-generation environments, which together underpin long-term growth for Mirion’s product portfolio.
For a deeper quantitative dive, you might explore ValueRay’s analyst platform, which aggregates peer-adjusted forecasts and valuation multiples for MIR.
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income: 26.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA 0.46 > 1.0 |
| NWC/Revenue: 121.9% < 20% (prev 35.12%; Δ 86.75% < -1%) |
| CFO/TA 0.04 > 3% & CFO 128.5m > Net Income 26.5m |
| Net Debt (299.3m) to EBITDA (195.3m): 1.53 < 3 |
| Current Ratio: 4.83 > 1.5 & < 3 |
| Outstanding Shares: last quarter (255.7m) vs 12m ago 23.70% < -2% |
| Gross Margin: 47.18% > 18% (prev 0.46%; Δ 4672 % > 0.5%) |
| Asset Turnover: 29.34% > 50% (prev 31.53%; Δ -2.19% > 0%) |
| Interest Coverage Ratio: 1.26 > 6 (EBITDA TTM 195.3m / Interest Expense TTM 46.4m) |
Altman Z'' 1.31
| A: 0.31 (Total Current Assets 1.39b - Total Current Liabilities 287.0m) / Total Assets 3.50b |
| B: -0.15 (Retained Earnings -530.0m / Total Assets 3.50b) |
| C: 0.02 (EBIT TTM 58.4m / Avg Total Assets 3.07b) |
| D: -0.37 (Book Value of Equity -587.1m / Total Liabilities 1.60b) |
| Altman-Z'' Score: 1.31 = BB |
Beneish M -3.05
| DSRI: 1.13 (Receivables 269.0m/220.3m, Revenue 902.3m/836.9m) |
| GMI: 0.98 (GM 47.18% / 46.35%) |
| AQI: 0.76 (AQ_t 0.55 / AQ_t-1 0.73) |
| SGI: 1.08 (Revenue 902.3m / 836.9m) |
| TATA: -0.03 (NI 26.5m - CFO 128.5m) / TA 3.50b) |
| Beneish M-Score: -3.05 (Cap -4..+1) = AA |
What is the price of MIR shares?
Over the past week, the price has changed by -3.10%, over one month by -4.48%, over three months by -12.63% and over the past year by +47.85%.
Is MIR a buy, sell or hold?
- StrongBuy: 3
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the MIR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 30.3 | 26% |
| Analysts Target Price | 30.3 | 26% |
| ValueRay Target Price | 31.7 | 31.6% |
MIR Fundamental Data Overview February 03, 2026
P/S = 6.7274
P/B = 3.3564
Revenue TTM = 902.3m USD
EBIT TTM = 58.4m USD
EBITDA TTM = 195.3m USD
Long Term Debt = 1.20b USD (from longTermDebt, last quarter)
Short Term Debt = 8.80m USD (from shortTermDebt, last quarter)
Debt = 1.23b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 299.3m USD (from netDebt column, last quarter)
Enterprise Value = 6.37b USD (6.07b + Debt 1.23b - CCE 933.2m)
Interest Coverage Ratio = 1.26 (Ebit TTM 58.4m / Interest Expense TTM 46.4m)
EV/FCF = 70.62x (Enterprise Value 6.37b / FCF TTM 90.2m)
FCF Yield = 1.42% (FCF TTM 90.2m / Enterprise Value 6.37b)
FCF Margin = 10.00% (FCF TTM 90.2m / Revenue TTM 902.3m)
Net Margin = 2.94% (Net Income TTM 26.5m / Revenue TTM 902.3m)
Gross Margin = 47.18% ((Revenue TTM 902.3m - Cost of Revenue TTM 476.6m) / Revenue TTM)
Gross Margin QoQ = 46.84% (prev 46.07%)
Tobins Q-Ratio = 1.82 (Enterprise Value 6.37b / Total Assets 3.50b)
Interest Expense / Debt = 0.72% (Interest Expense 8.90m / Debt 1.23b)
Taxrate = 21.0% (US default 21%)
NOPAT = 46.1m (EBIT 58.4m * (1 - 21.00%))
Current Ratio = 4.83 (Total Current Assets 1.39b / Total Current Liabilities 287.0m)
Debt / Equity = 0.67 (Debt 1.23b / totalStockholderEquity, last quarter 1.84b)
Debt / EBITDA = 1.53 (Net Debt 299.3m / EBITDA 195.3m)
Debt / FCF = 3.32 (Net Debt 299.3m / FCF TTM 90.2m)
Total Stockholder Equity = 1.58b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.86% (Net Income 26.5m / Total Assets 3.50b)
RoE = 1.68% (Net Income TTM 26.5m / Total Stockholder Equity 1.58b)
RoCE = 2.10% (EBIT 58.4m / Capital Employed (Equity 1.58b + L.T.Debt 1.20b))
RoIC = 1.90% (NOPAT 46.1m / Invested Capital 2.43b)
WACC = 9.35% (E(6.07b)/V(7.30b) * Re(11.13%) + D(1.23b)/V(7.30b) * Rd(0.72%) * (1-Tc(0.21)))
Discount Rate = 11.13% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 13.27%
[DCF Debug] Terminal Value 77.01% ; FCFF base≈76.6m ; Y1≈94.5m ; Y5≈161.0m
Fair Price DCF = 7.51 (EV 2.13b - Net Debt 299.3m = Equity 1.84b / Shares 244.4m; r=9.35% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 50.22 | EPS CAGR: 135.9% | SUE: 1.53 | # QB: 1
Revenue Correlation: 74.59 | Revenue CAGR: 6.24% | SUE: 0.19 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.12 | Chg30d=-0.005 | Revisions Net=+0 | Analysts=3
EPS next Year (2026-12-31): EPS=0.61 | Chg30d=-0.020 | Revisions Net=-1 | Growth EPS=+23.8% | Growth Revenue=+22.3%